Yu-Fen Tsai

Dr. Yu-Fen Tsai

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YTYu-Fen Tsai
Yu-Fen Tsai
CHChin-Mu Hsu
Chin-Mu Hsu
Hui-Hua HsiaoHui-Hua Hsiao
Hui-Hua Hsiao
Hepatitis B reactivation is a common complication in lymphoma patients under immunosuppressive treatment with potentially serious and life-threating consequences. In this review, we discuss the basis of chronic Hepatitis B virus (HBV) infection, the definition and risk factors for HBV reactivation. We overview the management of HBV reactivation based on virological status and immunosuppressive regimen risk stratification. We also highlight and update information about the HBV reactivation in lymphoma patients under novel agent treatment, including newer monoclonal antibodies, small molecule inhibitors, and even chimeric antigen receptor T-cell immunotherapy.

Verified
Journal Article
Open access
PDF file
YTYu-Fen Tsai
Yu-Fen Tsai
YLYi-Chang Liu
Yi-Chang Liu
CYChing-I Yang
Ching-I Yang
TCTzer Ming Chuang
Tzer Ming Chuang
YKYa-Lun Ke
Ya-Lun Ke
Hui-Hua HsiaoHui-Hua Hsiao
Hui-Hua Hsiao
Background: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. Methods: A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. Results: A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivariate analysis, poor performance status (p < 0.001), advanced stage (p < 0.001), less chemotherapy cycles (p < 0.001), and the presence of liver toxicity (p = 0.001) contributed to poor OS in DLBCL. Among HCV-positive DLBCL, the severity of liver fibrosis was the main risk factor related to death. Conclusion: Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.

13 December 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
YTYu-Fen Tsai
Yu-Fen Tsai
YWYen-Yun Wang
Yen-Yun Wang
Wan-Chi TsaiWan-Chi Tsai
Wan-Chi Tsai
CSChang-Wei Su
Chang-Wei Su
CHChing-Wei Hsu
Ching-Wei Hsu
Shyng-Shiou YuanShyng-Shiou Yuan
Shyng-Shiou Yuan
Background: Melatonin, produced by the pineal gland, is known for its antioxidant, oncostatic, and anti-inflammatory properties. However, studies on serum melatonin levels in different cancer types have yielded conflicting results, and little is known about the clinical significance of serum melatonin in oral squamous cell carcinoma (OSCC) in the Southern Asian population. Therefore, we explored its role in OSCC in this study. Methods: A total of 67 male OSCC patients and 78 healthy controls were enrolled in this case–control study. The serum levels of melatonin were determined by enzyme-linked immunosorbent assay (ELISA) and compared between the two groups. Results: The serum melatonin levels were significantly lower in OSCC patients compared with healthy controls (mean ± standard deviation, 15.0 ± 4.6 vs. 18.5 ± 11.8 pg/mL, p = 0.02). In the subgroup of age less than 55 years (mean age of OSCC), OSCC patients had a significantly decreased melatonin level than healthy controls (mean melatonin, 15.7 ± 12.6 vs. 20.8 ± 3.9 pg/mL, p = 0.02). Decreased serum melatonin (odds ratio (OR): 0.95, 95%CI: 0.91–0.99), alcohol consumption (OR: 29.02, 95%CI: 11.68–72.16), betel quid chewing (OR:136.44, 95%CI: 39.17–475.27), and cigarette smoking (OR:29.48, 95%CI: 11.06–78.60) all increased the risk of OSCC under univariate analyses of logistic regression. Betel quid chewing (OR: 45.98, 95%CI: 10.34–204.49) and cigarette smoking (OR:6.94, 95%CI: 1.60–30.16) were the independent risk factors for OSCC in Taiwan. In addition, a negative correlation between age and melatonin level was observed in healthy controls (Pearson r = −0.24, p = 0.03). However, the negative correlation was lost in patients with OSCC. Melatonin concentration had no association with the severity of OSCC. Conclusion: Overall, our study provides evidence that serum melatonin levels decreased in OSCC patients in Taiwan and the decreased level is much significant in young populations and suggests that the decreased melatonin was associated with OSCC, especially in young populations. Further studies are warranted to investigate whether melatonin can be a useful non-invasive screening tool for OSCC.

9 February 2017 in Turkish Journal of Hematology
Verified
Journal Article
Open access
Hui-Hua HsiaoHui-Hua Hsiao
Hui-Hua Hsiao
HWHui-Ching Wang
Hui-Ching Wang
YTYu-Fen Tsai
Yu-Fen Tsai
CHChien Hsiao
Chien Hsiao
SCShih-Feng Cho
Shih-Feng Cho
TLTa Chih Liu
Ta Chih Liu

1 May 2020 in Oral Oncology
Verified
Journal Article
Closed access
YTYu-Fen Tsai
Yu-Fen Tsai
YWYen-Yun Wang
Yen-Yun Wang
Shyng-Shiou YuanShyng-Shiou Yuan
Shyng-Shiou Yuan